New drug combo aims to save nerves in advanced ear cancer
NCT ID NCT07370337
First seen Jan 29, 2026 · Last updated May 01, 2026 · Updated 13 times
Summary
This study tests whether giving chemotherapy plus the drug tislelizumab before surgery can shrink advanced squamous cell carcinoma of the ear canal and help preserve important nerves like the facial nerve. About 50 adults with untreated, locally advanced tumors will receive this combination therapy. The goal is to improve cancer control and reduce damage to nearby structures during surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF EXTERNAL AUDITORY CANAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Li Wang
RECRUITINGShanghai, Shanghai Municipality, 200031, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.